1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020
Abstract Background Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age. Methods We conducted prospective, active surveillance among children ages 5–17 yea...
Gespeichert in:
Veröffentlicht in: | Open forum infectious diseases 2023-11, Vol.10 (Supplement_2) |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Supplement_2 |
container_start_page | |
container_title | Open forum infectious diseases |
container_volume | 10 |
creator | Sahni, Leila C Amarin, Justin Z Stopczynski, Tess Spieker, Andrew J Stewart, Laura S Staat, Mary A Quigley, Christina M Selvarangan, Rangaraj Schuster, Jennifer E Michaels, Marian G Williams, John V Szilagyi, Peter G Weinberg, Geoffrey A Englund, Janet A Klein, Eileen J Clopper, Benjamin R Moline, Heidi L Avadhanula, Vasanthi Munoz, Flor M Piedra, Pedro A Halasa, Natasha B Boom, Julie A |
description | Abstract
Background
Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age.
Methods
We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV).
Results
Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation.
Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020
Conclusion
Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic.
Disclosures
Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Res |
doi_str_mv | 10.1093/ofid/ofad500.1586 |
format | Article |
fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ofid_ofad500_1586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofad500.1586</oup_id><sourcerecordid>10.1093/ofid/ofad500.1586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1226-d89ca43a69549e15fe8da8470d9a577f7c3f400addd94cbe664d285d3b1cd4bf3</originalsourceid><addsrcrecordid>eNqNkE1OwzAQhSMEEqj0AOzmAA3YTpzES1QKrYQo4qcSq2jqHzCkcWWnVGXFHTgDF-MkJJQFSzYzo_fmvcUXRUeUHFMikhNnrGoHKk5ahRfZTnTAElbEheD57p97P-qH8EwIoZRwkouD6JPmnB_D2IWlbbCyb9hYVwcwzsONbkWPjfMbmFm_CjoALlz9CMMnWymva-Bf7x80hweNPoAzcPqowdbQPGm49joeTmeTs5gKuMZa6YWVMPI4-LGv9BpmKKWtNdyu_Ku2VYW17Ixm7fzLABihWVvPCCOH0Z7BKuj-7-5F9-eju-E4vpxeTIanl7GkjGWxKoTENMFM8FRoyo0uFBZpTpRAnucml4lJCUGllEjlXGdZqljBVTKnUqVzk_Qiuu2V3oXgtSmX3i7Qb0pKyg512aEuf1GXHeo2M9hm3Gr5j_dv47uDCQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sahni, Leila C ; Amarin, Justin Z ; Stopczynski, Tess ; Spieker, Andrew J ; Stewart, Laura S ; Staat, Mary A ; Quigley, Christina M ; Selvarangan, Rangaraj ; Schuster, Jennifer E ; Michaels, Marian G ; Williams, John V ; Szilagyi, Peter G ; Weinberg, Geoffrey A ; Englund, Janet A ; Klein, Eileen J ; Clopper, Benjamin R ; Moline, Heidi L ; Avadhanula, Vasanthi ; Munoz, Flor M ; Piedra, Pedro A ; Halasa, Natasha B ; Boom, Julie A</creator><creatorcontrib>Sahni, Leila C ; Amarin, Justin Z ; Stopczynski, Tess ; Spieker, Andrew J ; Stewart, Laura S ; Staat, Mary A ; Quigley, Christina M ; Selvarangan, Rangaraj ; Schuster, Jennifer E ; Michaels, Marian G ; Williams, John V ; Szilagyi, Peter G ; Weinberg, Geoffrey A ; Englund, Janet A ; Klein, Eileen J ; Clopper, Benjamin R ; Moline, Heidi L ; Avadhanula, Vasanthi ; Munoz, Flor M ; Piedra, Pedro A ; Halasa, Natasha B ; Boom, Julie A</creatorcontrib><description>Abstract
Background
Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age.
Methods
We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV).
Results
Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation.
Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020
Conclusion
Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic.
Disclosures
Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Geoffrey A. Weinberg, MD, Merck & Co: Honoraria Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofad500.1586</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27906,27907</link.rule.ids></links><search><creatorcontrib>Sahni, Leila C</creatorcontrib><creatorcontrib>Amarin, Justin Z</creatorcontrib><creatorcontrib>Stopczynski, Tess</creatorcontrib><creatorcontrib>Spieker, Andrew J</creatorcontrib><creatorcontrib>Stewart, Laura S</creatorcontrib><creatorcontrib>Staat, Mary A</creatorcontrib><creatorcontrib>Quigley, Christina M</creatorcontrib><creatorcontrib>Selvarangan, Rangaraj</creatorcontrib><creatorcontrib>Schuster, Jennifer E</creatorcontrib><creatorcontrib>Michaels, Marian G</creatorcontrib><creatorcontrib>Williams, John V</creatorcontrib><creatorcontrib>Szilagyi, Peter G</creatorcontrib><creatorcontrib>Weinberg, Geoffrey A</creatorcontrib><creatorcontrib>Englund, Janet A</creatorcontrib><creatorcontrib>Klein, Eileen J</creatorcontrib><creatorcontrib>Clopper, Benjamin R</creatorcontrib><creatorcontrib>Moline, Heidi L</creatorcontrib><creatorcontrib>Avadhanula, Vasanthi</creatorcontrib><creatorcontrib>Munoz, Flor M</creatorcontrib><creatorcontrib>Piedra, Pedro A</creatorcontrib><creatorcontrib>Halasa, Natasha B</creatorcontrib><creatorcontrib>Boom, Julie A</creatorcontrib><title>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</title><title>Open forum infectious diseases</title><description>Abstract
Background
Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age.
Methods
We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV).
Results
Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation.
Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020
Conclusion
Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic.
Disclosures
Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Geoffrey A. Weinberg, MD, Merck & Co: Honoraria Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support</description><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkE1OwzAQhSMEEqj0AOzmAA3YTpzES1QKrYQo4qcSq2jqHzCkcWWnVGXFHTgDF-MkJJQFSzYzo_fmvcUXRUeUHFMikhNnrGoHKk5ahRfZTnTAElbEheD57p97P-qH8EwIoZRwkouD6JPmnB_D2IWlbbCyb9hYVwcwzsONbkWPjfMbmFm_CjoALlz9CMMnWymva-Bf7x80hweNPoAzcPqowdbQPGm49joeTmeTs5gKuMZa6YWVMPI4-LGv9BpmKKWtNdyu_Ku2VYW17Ixm7fzLABihWVvPCCOH0Z7BKuj-7-5F9-eju-E4vpxeTIanl7GkjGWxKoTENMFM8FRoyo0uFBZpTpRAnucml4lJCUGllEjlXGdZqljBVTKnUqVzk_Qiuu2V3oXgtSmX3i7Qb0pKyg512aEuf1GXHeo2M9hm3Gr5j_dv47uDCQ</recordid><startdate>20231127</startdate><enddate>20231127</enddate><creator>Sahni, Leila C</creator><creator>Amarin, Justin Z</creator><creator>Stopczynski, Tess</creator><creator>Spieker, Andrew J</creator><creator>Stewart, Laura S</creator><creator>Staat, Mary A</creator><creator>Quigley, Christina M</creator><creator>Selvarangan, Rangaraj</creator><creator>Schuster, Jennifer E</creator><creator>Michaels, Marian G</creator><creator>Williams, John V</creator><creator>Szilagyi, Peter G</creator><creator>Weinberg, Geoffrey A</creator><creator>Englund, Janet A</creator><creator>Klein, Eileen J</creator><creator>Clopper, Benjamin R</creator><creator>Moline, Heidi L</creator><creator>Avadhanula, Vasanthi</creator><creator>Munoz, Flor M</creator><creator>Piedra, Pedro A</creator><creator>Halasa, Natasha B</creator><creator>Boom, Julie A</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231127</creationdate><title>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</title><author>Sahni, Leila C ; Amarin, Justin Z ; Stopczynski, Tess ; Spieker, Andrew J ; Stewart, Laura S ; Staat, Mary A ; Quigley, Christina M ; Selvarangan, Rangaraj ; Schuster, Jennifer E ; Michaels, Marian G ; Williams, John V ; Szilagyi, Peter G ; Weinberg, Geoffrey A ; Englund, Janet A ; Klein, Eileen J ; Clopper, Benjamin R ; Moline, Heidi L ; Avadhanula, Vasanthi ; Munoz, Flor M ; Piedra, Pedro A ; Halasa, Natasha B ; Boom, Julie A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1226-d89ca43a69549e15fe8da8470d9a577f7c3f400addd94cbe664d285d3b1cd4bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahni, Leila C</creatorcontrib><creatorcontrib>Amarin, Justin Z</creatorcontrib><creatorcontrib>Stopczynski, Tess</creatorcontrib><creatorcontrib>Spieker, Andrew J</creatorcontrib><creatorcontrib>Stewart, Laura S</creatorcontrib><creatorcontrib>Staat, Mary A</creatorcontrib><creatorcontrib>Quigley, Christina M</creatorcontrib><creatorcontrib>Selvarangan, Rangaraj</creatorcontrib><creatorcontrib>Schuster, Jennifer E</creatorcontrib><creatorcontrib>Michaels, Marian G</creatorcontrib><creatorcontrib>Williams, John V</creatorcontrib><creatorcontrib>Szilagyi, Peter G</creatorcontrib><creatorcontrib>Weinberg, Geoffrey A</creatorcontrib><creatorcontrib>Englund, Janet A</creatorcontrib><creatorcontrib>Klein, Eileen J</creatorcontrib><creatorcontrib>Clopper, Benjamin R</creatorcontrib><creatorcontrib>Moline, Heidi L</creatorcontrib><creatorcontrib>Avadhanula, Vasanthi</creatorcontrib><creatorcontrib>Munoz, Flor M</creatorcontrib><creatorcontrib>Piedra, Pedro A</creatorcontrib><creatorcontrib>Halasa, Natasha B</creatorcontrib><creatorcontrib>Boom, Julie A</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahni, Leila C</au><au>Amarin, Justin Z</au><au>Stopczynski, Tess</au><au>Spieker, Andrew J</au><au>Stewart, Laura S</au><au>Staat, Mary A</au><au>Quigley, Christina M</au><au>Selvarangan, Rangaraj</au><au>Schuster, Jennifer E</au><au>Michaels, Marian G</au><au>Williams, John V</au><au>Szilagyi, Peter G</au><au>Weinberg, Geoffrey A</au><au>Englund, Janet A</au><au>Klein, Eileen J</au><au>Clopper, Benjamin R</au><au>Moline, Heidi L</au><au>Avadhanula, Vasanthi</au><au>Munoz, Flor M</au><au>Piedra, Pedro A</au><au>Halasa, Natasha B</au><au>Boom, Julie A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</atitle><jtitle>Open forum infectious diseases</jtitle><date>2023-11-27</date><risdate>2023</risdate><volume>10</volume><issue>Supplement_2</issue><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract
Background
Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age.
Methods
We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV).
Results
Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation.
Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020
Conclusion
Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic.
Disclosures
Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Geoffrey A. Weinberg, MD, Merck & Co: Honoraria Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofad500.1586</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2328-8957 |
ispartof | Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2) |
issn | 2328-8957 2328-8957 |
language | eng |
recordid | cdi_crossref_primary_10_1093_ofid_ofad500_1586 |
source | DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central |
title | 1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A39%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1755.%20Hospitalizations%20for%20Respiratory%20Viruses%20among%20Children%205%E2%80%9317%20Years%20of%20Age%20in%20the%20Pre-COVID-19%20Pandemic%20Era,%20the%20New%20Vaccine%20Surveillance%20Network,%202016%E2%80%932020&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Sahni,%20Leila%20C&rft.date=2023-11-27&rft.volume=10&rft.issue=Supplement_2&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofad500.1586&rft_dat=%3Coup_cross%3E10.1093/ofid/ofad500.1586%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ofid/ofad500.1586&rfr_iscdi=true |